Manatuck Hill Partners’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.32M Buy
525,000
+75,000
+17% +$448K 1.13% 26
2026
Q2
$2.44M Buy
+450,000
New +$1.89M 0.81% 41
2025
Q4
– Sell
-629,800
Closed -$2.2M – 125
2025
Q3
$2.2M Buy
629,800
+380,000
+152% +$1.3M 0.73% 50
2025
Q2
$512K Sell
249,800
-100,200
-29% -$250K 0.19% 98
2025
Q1
$399K Buy
+350,000
New +$271K 0.18% 85

Other funds holding STLN

Manatuck Hill Partners's STLN Position: Q3 2026 in Review

Manatuck Hill Partners increased its Starling Oncology (STLN) stake by 17% in Q3 2026, buying an estimated $448K and bringing the position to 525,000 shares worth $3.32M. The position accounts for 1.13% of the portfolio, ranked #26.

Manatuck Hill Partners first reported a position in STLN in Q1 2025 and has held it in 5 quarters since. 130 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • Manatuck Hill Partners held 525,000 shares of Starling Oncology worth $3.32M as of Q3 2026.
  • Manatuck Hill Partners bought 75,000 Starling Oncology shares in Q3 2026, an estimated $448K.
  • Starling Oncology made up 1.13% of Manatuck Hill Partners's portfolio in Q3 2026, its #26 holding.
  • Manatuck Hill Partners first reported a position in Starling Oncology in Q1 2025 and has held it in 5 quarters since.
  • 130 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on Manatuck Hill Partners's 13F filing for Q3 2026, filed 16 Nov 2026.